Intra-Cellular Therapies (ITCI) Reports Q1 Loss of $0.63/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 8, 2019 7:35 AM EDTNEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2019, and provided a corporate update.
2018 was an important year for ITCI and our momentum has carried over into 2019, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. Our NDA for lumateperone for the treatment of schizophrenia is under review and we continue to make progress in preparing all areas of the Company for the potential launch... More
